Related Experiment Video
Updated: Oct 16, 2025
07:59
Training Dogs for Awake, Unrestrained Functional Magnetic Resonance Imaging
Published on: October 13, 2019
7.8K
Owner compliance in canine epilepsy.
Samantha Booth1, Sebastian Meller2, Rowena Ma Packer1
1Department of Clinical Science and Services, Royal Veterinary College, Hatfield, UK.
The Veterinary Record
|October 15, 2021
Summary
Owner compliance with canine epilepsy medication is low, with a median of 56% adherence. Factors like medication type and dosing frequency influence owner adherence to treatment plans for dogs with epilepsy.
Area of Science:
- Veterinary Medicine
- Pharmacology
- Animal Health
Background:
- Poor medication compliance is a major cause of treatment failure in human epilepsy.
- Canine idiopathic epilepsy management faces similar challenges with owner compliance.
Purpose of the Study:
- To analyze owner compliance in the pharmacological treatment of canine idiopathic epilepsy.
- To identify factors associated with owner non-compliance in canine epilepsy management.
Main Methods:
- Cross-sectional study analyzing prescription records for antiseizure drug tablets.
- Online survey assessing owner compliance in canine epilepsy groups.
- Assessing compliant prescription cycles and medication availability.
Main Results:
- Median owner compliance was 56% based on prescription monitoring.
- Polytherapy was associated with higher compliance rates than monotherapy (p=0.031).
- Lower daily dosing frequency correlated with better owner compliance (p=0.049).
Conclusions:
- Owner compliance in treating canine epilepsy is suboptimal.
- Veterinary surgeons must consider compliance issues in epilepsy management strategies.
- Addressing compliance barriers is crucial for improving treatment outcomes in canine epilepsy.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
362
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
362
01:13Seizures: Classification
682
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
682
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
522
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
522